Cancer

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety…

12 months ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer…

12 months ago

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024…

12 months ago

Mesa Laboratories Appoints Mark Capone to its Board of Directors

LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader…

12 months ago

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase…

12 months ago

Affimed Announces Leadership Change and Organizational Restructuring

Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount…

12 months ago

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments…

12 months ago

Prevention Over Cure: The Benefits of Being Proactive Vs. Reactive When It Comes to Health

Live the Way is Pioneering An Evidence-Based Approach to Health and Well-BeingLAS VEGAS, NV / ACCESSWIRE / January 5, 2024…

12 months ago

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the…

12 months ago

Metrodora Institute Announces New Chief Scientific Officer

Rohit Gupta, a Nationally Recognized Scientist, Biobank and Data Expert, is Named as Metrodora Institute's New Chief Scientific Officer and…

12 months ago